Jeremy Cetnar

Assistant Professor

  • 829 Citations
  • 10 h-Index
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Jeremy Cetnar is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 10 Similar Profiles
Prostatic Neoplasms Medicine & Life Sciences
docetaxel Medicine & Life Sciences
temozolomide Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Urinary Bladder Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Castration Medicine & Life Sciences
Drug Approval Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2008 2018

  • 829 Citations
  • 10 h-Index
  • 19 Article
  • 2 Letter
50 Citations (Scopus)

The impact of smoking and tp53 mutations in lung adenocarcinoma patients with targetable mutations—the lung cancer mutation consortium (LCMC2)

Aisner, D. L., Sholl, L. M., Berry, L. D., Rossi, M. R., Chen, H., Fujimoto, J., Moreira, A. L., Ramalingam, S. S., Villaruz, L. C., Otterson, G. A., Haura, E., Politi, K., Glisson, B., Cetnar, J., Garon, E. B., Schiller, J., Waqar, S. N., Sequist, L. V., Brahmer, J., Shyr, Y. & 7 others, Kugler, K., Wistuba, I. I., Johnson, B. E., Minna, J. D., Kris, M. G., Bunn, P. A. & Kwiatkowski, D. J., Mar 1 2018, In : Clinical Cancer Research. 24, 5, p. 1038-1047 10 p.

Research output: Contribution to journalArticle

Lung Neoplasms
High-Throughput Nucleotide Sequencing
38 Citations (Scopus)

Immune Checkpoint Inhibitors in Organ Transplant Patients

Kittai, A. S., Oldham, H., Cetnar, J. & Taylor, M., Jul 17 2017, (Accepted/In press) In : Journal of Immunotherapy.

Research output: Contribution to journalArticle

Graft Rejection
Death Domain Receptors
Cytotoxic T-Lymphocytes
Organ Transplantation

Is it time to convert the frequency of radiotherapy in small-cell lung cancer?

Mitin, T., Farrell, M., Holland, J., Cetnar, J. & Thomas, C., Oct 1 2017, In : The Lancet Oncology. 18, 10, p. e554

Research output: Contribution to journalLetter

Small Cell Lung Carcinoma
1 Citation (Scopus)
Drug Approval
Pharmaceutical Preparations
365 Citations (Scopus)

Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: A single-group, multicentre, phase 2 trial

Shaw, A. T., Gandhi, L., Gadgeel, S., Riely, G. J., Cetnar, J., West, H., Camidge, D. R., Socinski, M. A., Chiappori, A., Mekhail, T., Chao, B. H., Borghaei, H., Gold, K. A., Zeaiter, A., Bordogna, W., Balas, B., Puig, O., Henschel, V. & Ou, S. H. I., Feb 1 2016, In : The Lancet Oncology. 17, 2, p. 234-242 9 p.

Research output: Contribution to journalArticle

Non-Small Cell Lung Carcinoma
Advisory Committees